00:18 , Jul 2, 2019 |  BC Extra  |  Company News

Boehringer races to catch up in NASH through Yuhan deal

Boehringer is playing catch up in NASH through a preclinical deal with Yuhan that doubles its programs in the indication from one to two and marks its entry into combining therapeutic MOAs -- a strategy...
21:28 , May 24, 2019 |  BC Extra  |  Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
23:54 , May 8, 2019 |  BC Extra  |  Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

Takeda off-loads Xiidra, TachoSil  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will sell Xiidra lifitegrast to Novartis AG (NYSE:NVS; SIX:NOVN) for $3.4 billion up front, plus $1.9 billion in milestones. Takeda said divesting the dry eye...
22:44 , Apr 25, 2019 |  BC Extra  |  Clinical News

Gilead looks towards NASH combo data after selonsertib fails in second Phase III

Gilead's selonsertib has failed in another Phase III NASH trial, this time missing the primary endpoint in patients with a less severe stage of fibrosis. The company will focus on its combination strategy to treat...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
19:57 , Apr 12, 2019 |  BC Extra  |  Company News

Gilead, Novo team up to combine NASH compounds

A day after Gilead presented Phase II data at EASL for its cilofexor plus firsocostat combination to treat non-alcoholic steatohepatitis, the company partnered with Novo Nordisk to test the duo in combination with semaglutide in...
23:47 , Mar 21, 2019 |  BC Week In Review  |  Company News

Novo submits semaglutide applications for CV risk reduction

Novo Nordisk submitted an NDA to FDA for oral semaglutide as an adjunct to diet and exercise to improve blood sugar in Type II diabetics. The company used a Priority Review voucher for the application....
21:17 , Mar 5, 2019 |  BC Extra  |  Company News

Intarcia licenses Numab's autoimmune therapy

Ahead of an NDA resubmission for its Type II diabetes therapy, Intarcia exercised an option to license from Numab exclusive, worldwide rights to autoimmune disorder therapy, ND016. ND016 is a trispecific antibody fragment that blocks...
03:03 , Feb 15, 2019 |  BC Innovations  |  Tools & Techniques

Heartening predictors in diabetes

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and public and private stakeholders to pool thinking. As...
17:29 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Suzhou-based BrightGene raises pre-IPO round

BrightGene Bio-Medical Technology Co. Ltd. (Suzhou, China) raised RMB550 million ($80.3 million) in a venture round on Jan. 7. The company described the funding as a "pre-IPO round," but did not immediately respond to an...